REPAIR AND REGENERATION OF OCULAR TISSUE USING POSTPARTUM-DERIVED CELLS
First Claim
Patent Images
1. A method for treating a patient having a retinopathy or a retinal/macular disorder, the method comprising administering to the patient'"'"'s eye umbilicus-derived cells, in an amount effective to treat the retinopathy or a retinal/macular disorder, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and have the following characteristics:
- a. Potential for at least 40 population doublings in culture;
b. Attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin;
c. Production of vimentin and alpha-smooth muscle actin;
d. Production of CD10, CD13, CD44, CD73, and CD90; and
e. Expression of a gene, which is relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for a gene encoding interleukin 8 and reticulon 1.
10 Assignments
0 Petitions
Accused Products
Abstract
Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.
-
Citations
27 Claims
-
1. A method for treating a patient having a retinopathy or a retinal/macular disorder, the method comprising administering to the patient'"'"'s eye umbilicus-derived cells, in an amount effective to treat the retinopathy or a retinal/macular disorder, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and have the following characteristics:
-
a. Potential for at least 40 population doublings in culture; b. Attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin; c. Production of vimentin and alpha-smooth muscle actin; d. Production of CD10, CD13, CD44, CD73, and CD90; and e. Expression of a gene, which is relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for a gene encoding interleukin 8 and reticulon 1. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. A method for preventing the loss of photoreceptor cells associated with a retinopathy or a retinal/macular disorder in a patient, the method comprising administering to the patient'"'"'s eye umbilicus-derived cells, in an amount effective to prevent the loss of photoreceptor cells, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and have the following characteristics:
-
a. Potential for at least 40 population doublings in culture; b. Attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin; c. Production of vimentin and alpha-smooth muscle actin; d. Production of CD10, CD13, CD44, CD73, and CD90; and e. Expression of a gene, which is relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for a gene encoding interleukin 8 and reticulon 1. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
Specification